PIK3CA and neoplasm: Recently, SOLAR-1 study demonstrated that the combination of alpelisib and fulvestrant, a selective estrogen receptor degrader, prolonged progression-free survival among patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer13.